E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers E > Headlines for Eyegate Pharmaceuticals, Inc. > News item
Published on 5/24/2016 in the Prospect News PIPE Daily.

EyeGate will conduct at-the-market offering of 1.32 million shares

H.C. Wainwright will be the agent for offering

By Devika Patel

Knoxville, Tenn., May 24 – EyeGate Pharmaceuticals, Inc. said it negotiated an at-the-market offering of 1,319,289 common shares.

H.C. Wainwright & Co., LLC is the agent.

EyeGate is a Waltham, Mass.-based pharmaceutical company that is focused on therapeutics and drug-delivery systems for treating eye diseases.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.